The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Cancer Testing & Screening-Global Market Insights and Sales Trends 2024
Synopsis
Screening means checking your body for cancer before you have symptoms.
The global Cancer Testing & Screening market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Cancer Testing & Screening in various end use industries. The expanding demands from the Lung Cancer, Blood Cancer, Bone Cancer and Gall Bladder Cancer, are propelling Cancer Testing & Screening market. Magnetic Resonance Imaging (MRI), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Human Papillomavirus (HPV) Testing segment is estimated at % CAGR for the next seven-year period.
In the recent years, Next Generation Sequencing (NGS) is being widely used for detection of various types of cancer.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Cancer Testing & Screening, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Cancer Testing & Screening market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Cancer Testing & Screening market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Cancer Testing & Screening sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Cancer Testing & Screening covered in this report include Dias Orin, Epigenetics, Techlab, Positive Bioscience, Genextropy, M Genomics, 20/20 GeneSystems, AB SCIEX and Abbott Laboratories, etc.
The global Cancer Testing & Screening market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Dias Orin
Epigenetics
Techlab
Positive Bioscience
Genextropy
M Genomics
20/20 GeneSystems
AB SCIEX
Abbott Laboratories
Global Cancer Testing & Screening market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cancer Testing & Screening market, Segment by Type:
Magnetic Resonance Imaging (MRI)
Human Papillomavirus (HPV) Testing
Colonoscopy
Others
Global Cancer Testing & Screening market, by Application
Lung Cancer
Blood Cancer
Bone Cancer
Gall Bladder Cancer
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Cancer Testing & Screening companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Screening means checking your body for cancer before you have symptoms.
The global Cancer Testing & Screening market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Cancer Testing & Screening in various end use industries. The expanding demands from the Lung Cancer, Blood Cancer, Bone Cancer and Gall Bladder Cancer, are propelling Cancer Testing & Screening market. Magnetic Resonance Imaging (MRI), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Human Papillomavirus (HPV) Testing segment is estimated at % CAGR for the next seven-year period.
In the recent years, Next Generation Sequencing (NGS) is being widely used for detection of various types of cancer.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Cancer Testing & Screening, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Cancer Testing & Screening market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Cancer Testing & Screening market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Cancer Testing & Screening sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Cancer Testing & Screening covered in this report include Dias Orin, Epigenetics, Techlab, Positive Bioscience, Genextropy, M Genomics, 20/20 GeneSystems, AB SCIEX and Abbott Laboratories, etc.
The global Cancer Testing & Screening market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Dias Orin
Epigenetics
Techlab
Positive Bioscience
Genextropy
M Genomics
20/20 GeneSystems
AB SCIEX
Abbott Laboratories
Global Cancer Testing & Screening market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cancer Testing & Screening market, Segment by Type:
Magnetic Resonance Imaging (MRI)
Human Papillomavirus (HPV) Testing
Colonoscopy
Others
Global Cancer Testing & Screening market, by Application
Lung Cancer
Blood Cancer
Bone Cancer
Gall Bladder Cancer
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Cancer Testing & Screening companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Cancer Testing & Screening
1.1 Cancer Testing & Screening Market Overview
1.1.1 Cancer Testing & Screening Product Scope
1.1.2 Cancer Testing & Screening Market Status and Outlook
1.2 Global Cancer Testing & Screening Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Cancer Testing & Screening Market Size by Region (2018-2029)
1.4 Global Cancer Testing & Screening Historic Market Size by Region (2018-2023)
1.5 Global Cancer Testing & Screening Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Cancer Testing & Screening Market Size (2018-2029)
1.6.1 North America Cancer Testing & Screening Market Size (2018-2029)
1.6.2 Europe Cancer Testing & Screening Market Size (2018-2029)
1.6.3 Asia-Pacific Cancer Testing & Screening Market Size (2018-2029)
1.6.4 Latin America Cancer Testing & Screening Market Size (2018-2029)
1.6.5 Middle East & Africa Cancer Testing & Screening Market Size (2018-2029)
2 Cancer Testing & Screening Market by Type
2.1 Introduction
2.1.1 Magnetic Resonance Imaging (MRI)
2.1.2 Human Papillomavirus (HPV) Testing
2.1.3 Colonoscopy
2.1.4 Others
2.2 Global Cancer Testing & Screening Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Cancer Testing & Screening Historic Market Size by Type (2018-2023)
2.2.2 Global Cancer Testing & Screening Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Cancer Testing & Screening Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Cancer Testing & Screening Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Cancer Testing & Screening Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Cancer Testing & Screening Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Cancer Testing & Screening Revenue Breakdown by Type (2018-2029)
3 Cancer Testing & Screening Market Overview by Application
3.1 Introduction
3.1.1 Lung Cancer
3.1.2 Blood Cancer
3.1.3 Bone Cancer
3.1.4 Gall Bladder Cancer
3.1.5 Others
3.2 Global Cancer Testing & Screening Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Cancer Testing & Screening Historic Market Size by Application (2018-2023)
3.2.2 Global Cancer Testing & Screening Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Cancer Testing & Screening Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Cancer Testing & Screening Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Cancer Testing & Screening Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Cancer Testing & Screening Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Cancer Testing & Screening Revenue Breakdown by Application (2018-2029)
4 Cancer Testing & Screening Competition Analysis by Players
4.1 Global Cancer Testing & Screening Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cancer Testing & Screening as of 2022)
4.3 Date of Key Players Enter into Cancer Testing & Screening Market
4.4 Global Top Players Cancer Testing & Screening Headquarters and Area Served
4.5 Key Players Cancer Testing & Screening Product Solution and Service
4.6 Competitive Status
4.6.1 Cancer Testing & Screening Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Dias Orin
5.1.1 Dias Orin Profile
5.1.2 Dias Orin Main Business
5.1.3 Dias Orin Cancer Testing & Screening Products, Services and Solutions
5.1.4 Dias Orin Cancer Testing & Screening Revenue (US$ Million) & (2018-2023)
5.1.5 Dias Orin Recent Developments
5.2 Epigenetics
5.2.1 Epigenetics Profile
5.2.2 Epigenetics Main Business
5.2.3 Epigenetics Cancer Testing & Screening Products, Services and Solutions
5.2.4 Epigenetics Cancer Testing & Screening Revenue (US$ Million) & (2018-2023)
5.2.5 Epigenetics Recent Developments
5.3 Techlab
5.3.1 Techlab Profile
5.3.2 Techlab Main Business
5.3.3 Techlab Cancer Testing & Screening Products, Services and Solutions
5.3.4 Techlab Cancer Testing & Screening Revenue (US$ Million) & (2018-2023)
5.3.5 Positive Bioscience Recent Developments
5.4 Positive Bioscience
5.4.1 Positive Bioscience Profile
5.4.2 Positive Bioscience Main Business
5.4.3 Positive Bioscience Cancer Testing & Screening Products, Services and Solutions
5.4.4 Positive Bioscience Cancer Testing & Screening Revenue (US$ Million) & (2018-2023)
5.4.5 Positive Bioscience Recent Developments
5.5 Genextropy
5.5.1 Genextropy Profile
5.5.2 Genextropy Main Business
5.5.3 Genextropy Cancer Testing & Screening Products, Services and Solutions
5.5.4 Genextropy Cancer Testing & Screening Revenue (US$ Million) & (2018-2023)
5.5.5 Genextropy Recent Developments
5.6 M Genomics
5.6.1 M Genomics Profile
5.6.2 M Genomics Main Business
5.6.3 M Genomics Cancer Testing & Screening Products, Services and Solutions
5.6.4 M Genomics Cancer Testing & Screening Revenue (US$ Million) & (2018-2023)
5.6.5 M Genomics Recent Developments
5.7 20/20 GeneSystems
5.7.1 20/20 GeneSystems Profile
5.7.2 20/20 GeneSystems Main Business
5.7.3 20/20 GeneSystems Cancer Testing & Screening Products, Services and Solutions
5.7.4 20/20 GeneSystems Cancer Testing & Screening Revenue (US$ Million) & (2018-2023)
5.7.5 20/20 GeneSystems Recent Developments
5.8 AB SCIEX
5.8.1 AB SCIEX Profile
5.8.2 AB SCIEX Main Business
5.8.3 AB SCIEX Cancer Testing & Screening Products, Services and Solutions
5.8.4 AB SCIEX Cancer Testing & Screening Revenue (US$ Million) & (2018-2023)
5.8.5 AB SCIEX Recent Developments
5.9 Abbott Laboratories
5.9.1 Abbott Laboratories Profile
5.9.2 Abbott Laboratories Main Business
5.9.3 Abbott Laboratories Cancer Testing & Screening Products, Services and Solutions
5.9.4 Abbott Laboratories Cancer Testing & Screening Revenue (US$ Million) & (2018-2023)
5.9.5 Abbott Laboratories Recent Developments
6 North America
6.1 North America Cancer Testing & Screening Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Cancer Testing & Screening Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Cancer Testing & Screening Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Cancer Testing & Screening Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Cancer Testing & Screening Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Cancer Testing & Screening Market Dynamics
11.1 Cancer Testing & Screening Industry Trends
11.2 Cancer Testing & Screening Market Drivers
11.3 Cancer Testing & Screening Market Challenges
11.4 Cancer Testing & Screening Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
